Viatris stock reacts to Pacira deal announcement
Viatris (VTRS) moved back into focus after the company agreed to acquire Pacira BioSciences for about US$1.65b in cash, adding two marketed non opioid pain medicines to its portfolio.
Set against this Pacira announcement, Viatris trades at US$17.49 with a 30 day share price return of 3.61% and a year to date share price return of 40.37%. The 1 year total shareholder return of 81.65% hints that recent momentum follows a longer upswing in how investors have been reassessing both its earnings profile and perceived risks.
Scan how Viatris compares to other value driven healthcare stocks by reviewing the hand picked 29 high quality undervalued stocks that currently combine stronger balance sheets with cash flow support.
After an 81.65% 1 year total return and a US$1.65b Pacira commitment, the question now is whether Viatris still offers enough upside to justify the risks at this price.
Most Popular Narrative: 10% Undervalued
Viatris last closed at $17.49, while the most followed narrative pegs fair value at $19.40. This frames the Pacira deal against a stock that is already seen as modestly undervalued based on future earnings power and cash generation.
The company is well-positioned to benefit from sustained demand growth due to global population aging and increasing chronic disease prevalence, as demonstrated by positive late-stage pipeline developments in chronic disease, pain, and ophthalmology, setting the stage for long-term revenue growth through new branded and generic launches in large, underserved markets.
See why 46 investors see Viatris as 10% undervalued.
Result: Fair Value of $19.40 (UNDERVALUED)
Still, Viatris faces pressure from ongoing price erosion in major markets and heavy reliance on mature, off-patent products, which could blunt the bullish narrative.
Find out about the key risks to this Viatris narrative.
Next Steps
Mixed signals on Viatris so far. If you want to move quickly and shape your own view, start with the 3 key rewards and 1 important warning sign.
Looking for more Viatris sized investment ideas?
Do not stop your research at Viatris alone. Fresh ideas across different themes can sharpen your portfolio and help you spot opportunities you might otherwise miss.
- Target resilient income by reviewing companies in the 8 dividend fortresses that aim to combine generous payouts with durability.
- Spot financially sound operators early by scanning the list of solid balance sheet and fundamentals (25 results) before the crowd pays attention.
- Hunt for lesser known opportunities with strong fundamentals using the 20 high quality undiscovered gems while they still fly under most investors' radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com